BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 30244882)

  • 1. Radiation-Induced Lung Density Changes on CT Scan for NSCLC: No Impact of Dose-Escalation Level or Volume.
    Defraene G; La Fontaine M; van Kranen S; Reymen B; Belderbos J; Sonke JJ; De Ruysscher D
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(3):642-650. PubMed ID: 30244882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes of lung parenchyma density following high dose radiation therapy for thoracic carcinomas - an automated analysis of follow up CT scans.
    Schröder C; Engenhart-Cabillic R; Kirschner S; Blank E; Buchali A
    Radiat Oncol; 2019 Apr; 14(1):72. PubMed ID: 31036015
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
    Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
    J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additional PET/CT in week 5-6 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?
    Gillham C; Zips D; Pönisch F; Evers C; Enghardt W; Abolmaali N; Zöphel K; Appold S; Hölscher T; Steinbach J; Kotzerke J; Herrmann T; Baumann M
    Radiother Oncol; 2008 Sep; 88(3):335-41. PubMed ID: 18514339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study.
    van Der Wel A; Nijsten S; Hochstenbag M; Lamers R; Boersma L; Wanders R; Lutgens L; Zimny M; Bentzen SM; Wouters B; Lambin P; De Ruysscher D
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):649-55. PubMed ID: 15708242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concomitant Chemotherapy and Radiotherapy with SBRT Boost for Unresectable Stage III Non-Small Cell Lung Cancer: A Phase I Study.
    Higgins KA; Pillai RN; Chen Z; Tian S; Zhang C; Patel P; Pakkala S; Shelton J; Force SD; Fernandez FG; Steuer CE; Owonikoko TK; Ramalingam SS; Bradley JD; Curran WJ
    J Thorac Oncol; 2017 Nov; 12(11):1687-1695. PubMed ID: 28919394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update of a Prospective Study of Stereotactic Body Radiation Therapy for Post-Chemoradiation Residual Disease in Stage II/III Non-Small Cell Lung Cancer.
    Kumar S; Feddock J; Li X; Shearer AJ; Hall L; Shelton BJ; Arnold S; McGarry RC
    Int J Radiat Oncol Biol Phys; 2017 Nov; 99(3):652-659. PubMed ID: 29280459
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer.
    Thureau S; Dubray B; Modzelewski R; Bohn P; Hapdey S; Vincent S; Anger E; Gensanne D; Pirault N; Pierrick G; Vera P
    Radiat Oncol; 2018 Oct; 13(1):208. PubMed ID: 30352608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relationship of dose-volume histogram parameters and computed tomography grading of radiation-induced lung injury in patients with non-small cell lung cancer treated by three-dimensional conformal radiotherapy].
    Xing J; Li JB; Yu JM; Lu J; Xu M; Fan TY; Shao Q; Guo SF
    Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):676-81. PubMed ID: 19173909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial).
    van Diessen J; De Ruysscher D; Sonke JJ; Damen E; Sikorska K; Reymen B; van Elmpt W; Westman G; Fredberg Persson G; Dieleman E; Bjorkestrand H; Faivre-Finn C; Belderbos J
    Radiother Oncol; 2019 Feb; 131():166-173. PubMed ID: 30327236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time and dose-related changes in radiological lung density after concurrent chemoradiotherapy for lung cancer.
    Phernambucq EC; Palma DA; Vincent A; Smit EF; Senan S
    Lung Cancer; 2011 Dec; 74(3):451-6. PubMed ID: 21664713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A planning study of radiotherapy dose escalation of PET-active tumour volumes in non-small cell lung cancer patients.
    Møller DS; Khalil AA; Knap MM; Muren LP; Hoffmann L
    Acta Oncol; 2011 Aug; 50(6):883-8. PubMed ID: 21767188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pretreatment [18F]-fluoro-2-deoxy-glucose positron emission tomography maximum standardized uptake value as predictor of distant metastasis in early-stage non-small cell lung cancer treated with definitive radiation therapy: rethinking the role of positron emission tomography in personalizing treatment based on risk status.
    Nair VJ; MacRae R; Sirisegaram A; Pantarotto JR
    Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):312-8. PubMed ID: 24411602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of radiation-induced lung damage with CT scans: the possible benefit for radiogenomics.
    De Ruysscher D; Sharifi H; Defraene G; Kerns SL; Christiaens M; De Ruyck K; Peeters S; Vansteenkiste J; Jeraj R; Van Den Heuvel F; van Elmpt W
    Acta Oncol; 2013 Oct; 52(7):1405-10. PubMed ID: 23957564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive Dose Escalation using Serial Four-dimensional Positron Emission Tomography/Computed Tomography Scans during Radiotherapy for Locally Advanced Non-small Cell Lung Cancer.
    Yap ML; Sun A; Higgins J; Clarke K; Marshall A; Becker N; Le LW; Vines DC; Bezjak A; Bissonnette JP
    Clin Oncol (R Coll Radiol); 2016 Dec; 28(12):e199-e205. PubMed ID: 27637725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of lung function after chemo-radiotherapy for NSCLC measured by perfusion SPECT/CT: Correlation with radiation dose and clinical morbidity.
    Farr KP; Møller DS; Khalil AA; Kramer S; Morsing A; Grau C
    Acta Oncol; 2015; 54(9):1350-4. PubMed ID: 26203930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A clinical study of shrinking field radiation therapy based on (18)F-FDG PET/CT for stage III non-small cell lung cancer.
    Ding X; Li H; Wang Z; Huang W; Li B; Zang R; Sun H; Yi Y
    Technol Cancer Res Treat; 2013 Jun; 12(3):251-7. PubMed ID: 23289475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung density changes after stereotactic radiotherapy: a quantitative analysis in 50 patients.
    Palma DA; van Sörnsen de Koste J; Verbakel WF; Vincent A; Senan S
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):974-8. PubMed ID: 20932655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stereotactic Body Radiation Therapy Boost After Concurrent Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer: A Phase 1 Dose Escalation Study.
    Hepel JT; Leonard KL; Safran H; Ng T; Taber A; Khurshid H; Birnbaum A; ; Wazer DE; DiPetrillo T
    Int J Radiat Oncol Biol Phys; 2016 Dec; 96(5):1021-1027. PubMed ID: 27745983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
    Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M
    J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.